Iron homeostasis in chronic inflammation

Acta Physiologica Hungarica

Volumn 94, Issue 1-2, 2007, Pages 95-106

  Balla, Jozsef ^a   Jeney, V ^a   Varga, Zs ^a   Komodi E ^a   Nagy, E ^a   Balla, Gy ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Erythropoiesis; Ferritin; Iron; Iron metabolism; Iron recycling; Transferrin; Transferrin receptor

Indexed keywords

ANTIMICROBIAL CATIONIC PEPTIDE; CATION TRANSPORT PROTEIN; FERRITIN; HEPCIDIN; IRON; IRON REGULATORY PROTEIN 1; IRON REGULATORY PROTEIN 2; SOLUTE CARRIER FAMILY 11 (PROTON COUPLED DIVALENT METAL ION TRANSPORTERS), MEMBER 2; SOLUTE CARRIER FAMILY 11- (PROTON-COUPLED DIVALENT METAL ION TRANSPORTERS), MEMBER 2; TRANSFERRIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL; BIOSYNTHESIS; CHRONIC KIDNEY FAILURE; ERYTHROCYTE; ERYTHROCYTE LIFESPAN; ERYTHROPOIESIS; HOMEOSTASIS; HUMAN; INFLAMMATION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; CATION TRANSPORT PROTEINS; ERYTHROCYTE AGING; ERYTHROCYTES; ERYTHROPOIESIS; FERRITINS; HOMEOSTASIS; HUMANS; INFLAMMATION; IRON; IRON REGULATORY PROTEIN 1; IRON REGULATORY PROTEIN 2; KIDNEY FAILURE, CHRONIC; RECEPTORS, TRANSFERRIN; TRANSFERRIN;

EID: 34248213547     PISSN: 0231424X     EISSN: 15882683     Source Type: Journal    
DOI: 10.1556/APhysiol.94.2007.1-2.9     Document Type: Review

References (71)

1. Kimmel PL, Phillips TM, Simmens SJ, Peterson RA, Weihs KL, Alleyne S, Cruz I, Yanovski JA, Veis JH: Immunologic function and survival in hemodialysis patients. Kidney Int. 54, 236-244 (1998)
2. Barany P, Divino Filho JC, Bergstrom J: High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am. J. Kidney Dis. 29, 565-568 (1997)
3. Gunnell J, Yeun JY, Depner TA, Kaysen GA: Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am. J. Kidney Dis. 33, 63-72 (1999)
4. Richardson DR, Ponka P: The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim. Biophys. Acta 1331, 1-40 (1997)
5. Andrews NC: Disorders of iron metabolism. N. Engl. J. Med. 341, 1986-1995 (1999)
6. Sheth S, Brittenham GM: Genetic disorders affecting proteins of iron metabolism: clinical implications. Annu. Rev. Med. 51, 443-464 (2000)
7. Mareschal JC, Rama R, Crichton RR: The role of ceruloplasmin in Fe(III-transferrin formation in vitro. FEBS Lett. 110, 268-270 (1980)
8. Levy JE, Jin O, Fujiwara Y, Kuo F, Andrews NC: Transferrin receptor is necessary for development of erythrocytes and the nervous system. Nat. Genet. 21, 396-399 (1999)
9. Kawabata H, Yang R, Hirama T, Vuong PT, Kawano S, Gombart AF, Koeffler HP: Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family. J. Biol. Chem. 274, 20826-20832 (1999)
10. Gunshin H, Mackenzie B, Berger UV, Gunshin Y, Romero MF, Boron WF, Nussberger S, Gollan JL, Hediger MA: Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 388, 482-488 (1997)
11. Fleming MD, Trenor CC 3rd, Su MA, Foernzler D, Beier DR, Dietrich WF, Andrews NC: Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat. Genet. 16, 383-386 (1997)
12. Harrison PM, Arosio P: The ferritins: molecular properties, iron storage function and cellular regulation. Biochim. Biophys. Acta 1275, 161-203 (1996)
13. Balla G, Jacob HS, Balla J, Rosenberg M, Nath K, Apple F, Eaton JW, Vercellotti GM: Ferritin: a cytoprotective antioxidant strategem of endothelium. J. Biol. Chem. 267, 18148-18153 (1992)
14. Balla J, Balla G, Jeney V, Kakuk G, Jacob HS, Vercellotti GM: Ferriporphyrins and endothelium: a 2-edged sword-promotion of oxidation and induction of cytoprotectants. Blood 95, 3442-3450 (2000)
15. Rouault T, Klausner R: Regulation of iron metabolism in eukaryotes. Curr. Top Cell Regul. 35, 1-19 (1997)
16. Eisenstein RS: Iron regulatory proteins and the molecular control of mammalian iron metabolism. Annu. Rev. Nutr. 20, 627-662 (2000)
17. Kawabata H, Germain RS, Ikezoe T, Tong X, Green EM, Gombart AF, Koeffler HP: Regulation of expression of murine transferrin receptor 2. Blood 98, 1949-1954 (2001)
18. Ferguson BJ, Skikne BS, Simpson KM, Baynes RD, Cook JD: Serum transferrin receptor distinguishes the anemia of chronic disease from iron deficiency anemia. J. Lab. Clin. Med. 119, 385-390 (1992)
19. Tessitore N, Solero GP, Lippi G, Bassi A, Faccini GB, Bedogna V, Gammaro L, Brocco G, Restivo G, Bernich P, Lupo A, Maschio G: The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol. Dial. Transplant. 16, 1416-1423 (2001)
20. Tenhunen R, Marver HS, Schmid R: The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc. Natl. Acad. Sci. USA 61, 748-755 (1968)
21. Maines MD, Kappas A: Cobalt induction of hepatic heme oxygenase; with evidence that cytochrome P-450 is not essential for this enzyme activity. Proc. Natl. Acad. Sci. USA 4293-4297 (1974)
22. Abraham NG, Mitrione SM, Hodgson WJ, Levere RD, Shibahara S: Expression of heme oxygenase in hemopoiesis. Adv. Exp. Med. Biol. 241, 97-116 (1988)
23. Baranano DE, Wolosker H, Bae BI, Barrow RK, Snyder SH, Ferris CD: A mammalian iron ATPase induced by iron. J. Biol. Chem. 275, 15166-15173 (2000)
24. Abboud S, Haile DJ: A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J. Biol. Chem. 275, 19906-19912 (2000)
25. Conrad ME, Umbreit JN: Iron absorption and transport - an update. Am. J. Hematol. 64, 287-298 (2000)
26. Roy CN, Enns CA: Iron homeostasis: new tales from the crypt. Blood 96, 4020-4027 (2000)
27. Donovan A, Brownlie A, Zhou Y et al.: Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 403, 776-781 (2000)
28. Vulpe CD, Kuo YM, Murphy TL, Cowley L, Askwith C, Libina N, Gitschier J, Anderson GJ: Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat. Genet. 21, 195-199 (1999)
29. Alvarez-Hernandez X, Liceaga J, McKay IC, Brock JH: Induction of hypoferremia and modulation of macrophage iron metabolism by tumor necrosis factor. Lab. Invest. 61, 319-322 (1989)
30. Feelders RA, Vreugdenhil G, Eggermont AM, Kuiper-Kramer PA, van Eijk HG, Swaak AJ: Regulation of iron metabolism in the acute-phase response: interferon gamma and tumour necrosis factor alpha induce hypoferraemia, ferritin production and a decrease in circulating transferrin receptors in cancer patients. Eur. J. Clin. Invest. 28, 520-527 (1998)
31. Stam TC, Swaak AJ, Kruit WH, Eggermont AM: Regulation of ferritin: a specific role for interferonalpha (IFN-alpha)? The acute phase response in patients treated with IFN-alpha-2b. Eur. J. Clin. Invest. 32, Suppl 1, 79-83 (2002)
32. Drapier JC, Hirling H, Wietzerbin J, Kaldy P, Kuhn LC: Biosynthesis of nitric oxide activates iron regulatory factor in macrophages. EMBO J. 12, 3643-3649 (1993)
33. Pantopoulos K, Hentze MW: Nitric oxide signaling to iron-regulatory protein: direct control of ferritin mRNA translation and transferrin receptor mRNA stability in transfected fibroblasts. Proc. Natl. Acad. Sci. USA 92, 1267-1271 (1995)
34. Juckett MB, Weber M, Balla J, Jacob HS, Vercellotti GM: Nitric oxide donors modulate ferritin and protect endothelium from oxidative injury. Free Radic. Biol. Med. 20, 63-73 (1996)
35. Bouton C, Raveau M, Drapier JC: Modulation of iron regulatory protein functions. Further insights into the role of nitrogen- and oxygen-derived reactive species. J. Biol. Chem. 271, 2300-2306 (1996)
36. Phillips JD, Kinikini DV, Yu Y, Guo B, Leibold EA: Differential regulation of IRP1 and IRP2 by nitric oxide in rat hepatoma cells. Blood 87, 2983-2992 (1996)
37. Weiss G, Bogdan C, Hentze MW: Pathways for the regulation of macrophage iron metabolism by the anti-inflammatory cytokines IL-4 and IL-13. J. Immunol. 158, 420-425 (1997)
38. Recalcati S, Taramelli D, Conte D, Cairo G: Nitric oxide-mediated induction of ferritin synthesis in J774 macrophages by inflammatory cytokines: role of selective iron regulatory protein-2 downregulation. Blood 91, 1059-1066 (1998)
39. Bouton C, Oliveira L, Drapier JC: Converse modulation of IRP1 and IRP2 by immunological stimuli in murine RAW 264.7 macrophages. J. Biol. Chem. 273, 9403-9408 (1998)
40. Kim S, Ponka P: Effects of interferon-gamma and lipopolysaccharide on macrophage iron metabolism are mediated by nitric oxide-induced degradation of iron regulatory protein 2. J. Biol. Chem. 275, 6220-6226 (2000)
41. Kim S, Ponka P: Nitrogen monoxide-mediated control of ferritin synthesis: implications for macrophage iron homeostasis. Proc. Natl. Acad. Sci. USA 99, 12214-12219 (2002)
42. Pantopoulos K, Hentze MW: Rapid responses to oxidative stress mediated by iron regulatory protein. EMBO J. 14, 2917-2924 (1995)
43. Cairo G, Castrusini E, Minotti G, Bernelli-Zazzera A: Superoxide and hydrogen peroxide-dependent inhibition of iron regulatory protein activity: a protective stratagem against oxidative injury. FASEB J. 10, 1326-1335 (1996)
44. Iwai K, Drake SK, Wehr NB, Weissman AM, LaVaute T, Minato N, Klausner RD, Levine RL, Rouault TA: Iron-dependent oxidation, ubiquitination, and degradation of iron regulatory protein 2: implications for degradation of oxidized proteins. Proc. Natl. Acad. Sci. USA 95, 4924-4928 (1998)
45. Miller LL, Miller SC, Torti SV, Tsuji Y, Torti FM: Iron-independent induction of ferritin H chain by tumor necrosis factor. Proc. Natl. Acad. Sci. USA 88, 4946-4950 (1991)
46. Tsuji Y, Miller LL, Miller SC, Torti SV, Torti FM: Tumor necrosis factor-alpha and interleukin 1-alpha regulate transferrin receptor in human diploid fibroblasts. Relationship to the induction of ferritin heavy chain. J. Biol. Chem. 266, 7257-7261 (1991)
47. Hershko C: Storage iron regulation. Prog. Hematol. 10, 105-148
48. Fillet G, Beguin Y, Baldelli L: Model of reticuloendothelial iron metabolism in humans: abnormal behavior in idiopathic hemochromatosis and in inflammation. Blood 74, 844-851 (1989)
49. Kooistra MP, Niemantsverdriet EC, van Es A, Mol-Beermann NM, Struyvenberg A, Marx JJ: Iron absorption in erythropoietin-treated haemodialysis patients: Effects of iron availability, inflammation and aluminium. Nephrol. Dial. Transplant. 13, 82-88 (1998)
50. Ganz, T: Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 102, 783-788 (2003)
51. Kulaksiz H, Gehrke SG., Janetzko A, Rost D, Bruckner T, Kallinowski B, Stremmel W: Pro-hepcidin: expression and cell specific localisation in the liver and its regulation in hereditary haemochromatosis, chronic renal insufficiency, and renal anaemia. Gut 53, 735-743 (2004)
52. Taes YE, Wuyts B, Boelaert JR, De Vriese AS, Delanghe JR: Prohepcidin accumulates in renal insufficiency. Clin. Chem. Lab. Med. 42, 387-389 (2004)
53. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am. J. Kidney Dis. 30(Suppl 3), S192-S240 (1997)
54. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol. Dial. Transplant. 14(Suppl 5), 1-50 (1999)
55. Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, Zazra JJ, Anandan JV, Gupta A: Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J. Am. Soc. Nephrol. 11, 530-538 (2000)
56. Braun J, Hammerschmidt M, Schreiber M, Heidler R, Horl WH: Is zinc protoporphyrin an indicator of iron-deficient erythropoiesis in maintenance haemodialysis patients? Nephrol. Dial. Transplant. 11, 492-497 (1996)
57. Macdougall IC, Cavill I, Hulme B, Bain B, McGregor E, McKay P, Sanders E, Coles GA, Williams JD: Detection of functional iron deficiency during erythropoietin treatment: a new approach. Br. Med. J. 304, 225-226 (1992)
58. Bovy C, Tsobo C, Crapanzano L, Rorive G, Beguin Y, Albert A, Paulus JM: Factors determining the percentage of hypochromic red blood cells in hemodialysis patients. Kidney Int. 56, 1113-1119 (1999)
59. Tessitore N, Solero GP, Lippi G, Bassi A, Faccini GB, Bedogna V, Gammaro L, Brocco G, Restivo G, Bernich P, Lupo A, Maschio G: The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol. Dial. Transplant. 16, 1416-1423 (2001)
60. Cullen P, Soffker J, Hopfl M, Bremer C, Schlaghecken R, Mehrens T, Assmann G, Schaefer RM: Hypochromic red cells and reticulocyte haemglobin content as markers of iron-deficient erythropoiesis in patients undergoing chronic haemodialysis. Nephrol. Dial. Transplant. 14, 659-665 (1999)
61. Fishbane S, Galgano C, Langley RC Jr, Canfield W, Maesaka JK: Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int. 52, 217-222 (1997)
62. Mittman N, Sreedhara R, Mushnick R, Chattopadhyay J, Zelmanovic D, Vaseghi M, Avram MM: Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. Am. J. Kidney Dis. 30, 912-922 (1997)
63. Davis BH, Bigelow NC: Flow cytometric reticulocyte quantification using thiazole orange provides clinically useful reticulocyte maturity index. Arch. Pathol. Lab. Med. 113, 684-689 (1989)
64. Chuang CL, Liu RS, Wei YH, Huang TP, Tarng DC: Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients. Nephrol. Dial. Transplant. 18, 370-377 (2003)
65. Means RT Jr, Krantz SB.: Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 80, 1639-1647 (1992)
66. Wang CQ, Udupa KB, Lipschitz DA: Interferon-gamma exerts its negative regulatory effect primarily on the earliest stages of murine erythroid progenitor cell development. J. Cell Physiol. 162, 134-138 (1995)
67. Allen DA, Breen C, Yaqoob MM, Macdougall IC: Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-gamma and TNF-alpha. J. Investig. Med. 47, 204-211 (1999)
68. Kato A, Odamaki M, Takita T, Furuhashi M, Maruyama Y, Hishida A: High blood soluble receptor p80 for tumour necrosis factor-alpha is associated with erythropoietin resistance in haemodialysis patients. Nephrol. Dial. Transplant. 16, 1838-1844 (2001)
69. Maciejewski JP, Selleri C, Sato T, Cho HJ, Keefer LK, Nathan CF, Young NS: Nitric oxide suppression of human hematopoiesis in vitro. Contribution to inhibitory action of interferon-gamma and tumor necrosis factor-alpha. J. Clin. Invest. 96, 1085-1092 (1995)
70. Cooper AC, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC: Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma, TNF-alpha, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy. J. Am. Soc. Nephrol. 14, 1776-1784 (2003)
71. Means RT Jr, Krantz SB: Inhibition of human erythroid colony-forming units by gamma interferon can be corrected by recombinant human erythropoietin. Blood 78, 2564-2577 (1991)